140 Combination of PI3K inhibitor BAY 80-6946 and allosteric MEK inhibitor BAY 86-9766 (RDEA119), a promising approach for the treatment of colorectal cancers

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Ejc Supplements

• Publication date

  2010-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1359-6349(10)71845-0
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Targeting the phosphatidylinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signalling pathways to enhance chemoradiotherapy in locally advanced rectal cancer.

  2025cites this paper
• Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

  2020influential citation
• A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib

  2017influential citation